Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.
10.5306/wjco.v10.i9.303
Saved in:
Main Authors: | Zhou, Jianbiao, Chng, Wee-Joo |
---|---|
Other Authors: | DEAN'S OFFICE (MEDICINE) |
Format: | Editorial |
Published: |
Baishideng Publishing Group Inc.
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/229011 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Management of treatment-emergent peripheral neuropathy in multiple myeloma
by: Richardson, P.G., et al.
Published: (2016) -
Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
by: Spencer, Andrew, et al.
Published: (2023) -
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas
by: Jeitany, Maya, et al.
Published: (2022) -
Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors
by: Lim, Jhin Jieh, et al.
Published: (2023) -
Proteasome inhibition: An early or late event in nitric oxide-induced neuronal death?
by: Peng, Z.F., et al.
Published: (2011)